CD19 and B-cell non-Hodgkin lymphoma: In another study by Enblad et al., which was a phase I/IIa trial with CD-19 – targeting CAR-T cells of the third generation in patients with B-cell lymphomas and leukemias they showed similar results (NCT02132624).